罗氟司特进医保了吗？

Roflumilast is the only oral phosphodiesterase-4 inhibitor available for the treatment of chronic obstructive pulmonary disease (COPD). Previous studies on the drug have been conducted mainly in people from European and North American countries. In order to clarify the effectiveness and safety of using roflumilast in this group of people, mainly Chinese. A research team led by Zhong Nanshan from the First Affiliated Hospital of Guangzhou Medical University and Guangzhou Institute of Respiratory Diseases conducted a study, the results of which were published online in the journal CHEST on October 17, 2013. The results show that the treatment can significantly improve the lung function of Asian COPD patients and is well tolerated; it can provide an ideal treatment option for Asian patients with severe to very severe COPD.

Roflumilast is a long-acting inhibitor of selective phosphodiesterase type 4 (PDE-4) and has anti-inflammatory effects. Phosphodiesterases are a family of enzymes including at least 11 subtypes of enzymes that catalyze the decomposition of the messenger molecules cyclic adenosine monophosphate and/or cyclic guanosine monophosphate. Phosphodiesterase-4 is a major cyclic adenosine monophosphate metabolic enzyme in inflammatory and immune cells, and phosphodiesterase-4 inhibitors have broad anti-inflammatory activities including inhibiting the release of inflammatory mediators and inhibiting immune cell activation. In addition, phosphodiesterase-4 inhibitors have also been shown to have therapeutic effects in animal models of airway inflammation.

Roflumilast selectively inhibits PDE4, blocks inflammatory response signaling, and thereby inhibits damage to lung tissue caused by respiratory diseases such as COPD and asthma: cyclic nucleotides cAMP and cGMP are important second messengers in cells and play an important role in biological responses caused by various extracellular signals including hormones, autoactive substances and neurotransmitters.

Are you covered by medical insurance? Currently, roflumilast is not marketed in China and is not eligible for medical insurance. In other words, if patients want to purchase the drug, they must go abroad to purchase it. Traveling abroad to buy medicines is a long journey and requires a lot of manpower and material resources. Coupled with the huge medical expenses, many patient families are overwhelmed. However, according to Medical Companion Travel, 500μg*90 tablets of roflumilast costs approximately $2,850 per box. Since the exchange rate has been in a state of fluctuation for a long time, the price fluctuates with the exchange rate and is not static. For more information about roflumilast, please contact Medical Companion Travel for details.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.